delta-Opioid receptor stimulation enhances the growth of neonatal rat ventricular myocytes via the extracellular signal-regulated kinase pathway

Clin Exp Pharmacol Physiol. 2008 Jan;35(1):97-102. doi: 10.1111/j.1440-1681.2007.04831.x.

Abstract

1. The aims of the present study were to determine whether delta-opioid receptor stimulation enhanced proliferation of and to investigate the role of the extracellular signal-regulated kinase (ERK) pathway in ventricular myocytes from neonatal rats. 2. At concentratins ranging from 10 nmol/L to 10 micromol/L, [D-Ala2,D-Leu5]enkephalin (DADLE) concentration-dependently promoted myocardial growth and DNA synthesis and altered the cytoskeleton. 3. At 1 micromol/L, DADLE also increased the expression and phosphorylation of ERK. 4. These effects of 1 micromol/L DADLE were abolished by 10 micromol/L naltrindole, a selective delta-opioid receptor antagonist, 10 nmol/L U0126, a selective ERK antagonist, 1 micromol/L staurosporine, an inhibitor of protein kinase (PK) C, and 100 micromol/L Rp-adenosine 3',5'-cyclic monophosphorothioate triethylammonium salt hydrate (Rp-cAMPS), an inhibitor of PKA. 5. In conclusion, delta-opioid receptor stimulation enhances the proliferation and development of the ventricular myocytes of neonatal rats. The ERK pathway and related signalling mechanisms, namely PKC and PKA, are involved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics, Opioid / pharmacology*
  • Animals
  • Animals, Newborn
  • Butadienes / pharmacology
  • Cell Proliferation / drug effects*
  • Cells, Cultured
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cytoskeleton / drug effects
  • Dose-Response Relationship, Drug
  • Enkephalin, Leucine-2-Alanine / pharmacology*
  • Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors
  • Extracellular Signal-Regulated MAP Kinases / metabolism*
  • Heart Ventricles / drug effects
  • Heart Ventricles / metabolism
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / metabolism
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Nitriles / pharmacology
  • Phosphorylation
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, delta / agonists*
  • Receptors, Opioid, delta / metabolism
  • Signal Transduction / drug effects*
  • Staurosporine / pharmacology
  • Thionucleotides / pharmacology
  • Time Factors

Substances

  • Analgesics, Opioid
  • Butadienes
  • Narcotic Antagonists
  • Nitriles
  • Protein Kinase Inhibitors
  • Receptors, Opioid, delta
  • Thionucleotides
  • U 0126
  • adenosine-3',5'-cyclic phosphorothioate
  • Naltrexone
  • Enkephalin, Leucine-2-Alanine
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
  • Extracellular Signal-Regulated MAP Kinases
  • naltrindole
  • Staurosporine